-
Document de presse | 2006.09.04
Rapid Diagnosis Tests for Meningococcal Meningitis
New tests for rapid diagnosis of meningococcal meningitis have been developed and validated by the Institut Pasteur in Paris, and by CERMES in Niamey (Niger), an associated institute in the International Network of Instituts Pasteur. These tests can be used at the patient's bedside, and are formatted in two dipsticks, which can diagnose 4 serogroups of meningococcus (A, C, W135 and Y). They...
-
Document de presse | 2006.05.22
Origine and microevolution of the Chikungunya viruses responsible for the Indian Ocean outbreaks Complete sequencing of the genomes of 6 viral strains
Researchers at the Institut Pasteur have managed to retrace the origin and evolution of the Chikungunya virus in the Indian Ocean through complete sequencing of the genome of six viral strains isolated from patients from Reunion Island and the Seychelles, as well as through partial sequencing of the viral protein E1 from 127 patients from the Indian Ocean islands (Reunion,Madagascar, Seychelles,...
-
Document de presse | 2006.02.05
HHS and Institut Pasteur Partner On Pandemic Influenza Preparedness
Paris, France—The U.S. Department of Health and Human Services (HHS) and Institut Pasteur (IP) today agreed to carry out joint activities, beginning in Southeast Asia, to strengthen global capacity to detect influenza viruses that could have the potential to trigger a human pandemic. Press release Paris, febuary 6, 2006 The Memorandum of Understanding (MOU),...
-
Document de presse | 2005.11.27
Glaxosmithkline Biologicals Licenses Institut Pasteur Technology to develop AIDS Vaccine; Innovative Public-Private Partenership will use Measles Vaccine As starting point
Using an ancient scourge to combat a new one, researchers from GlaxoSmithKline Biologicals and the Institut Pasteur announced a new European collaboration to develop an AIDS vaccine by fusing genes from the human immunodeficiency virus (HIV) onto an existing measles vaccine. Press release Paris, november 28, 2005 GSK Biologicals will license the measles vaccine vector...
-
Document de presse | 2005.11.07
Malaria: an innovative approach for developing a vaccine
Researchers at the Institut Pasteur have developed a novel approach in order to design a vaccine candidate against malaria based on clinical observations in humans. Among populations infected by malaria, they sought to discover which antigens trigger immune responses capable of eliminating the Plasmodium falciparum parasite. In a phase I clinical trial, they showed that protective antibodies...
-
Document de presse | 2005.07.06
The Molecular Basis of Nicotine Dependence Unveiled
Researchers from the Institut Pasteur associated with the CNRS have revealed for the first time in work published in Nature how and where nicotine dependence develops in mice. Dependence is linked to the expression of a receptor molecule for nicotine that is also involved in individuals' cognitive abilities. Therefore for the first time, they have established the existence of anatomical and...
-
Document de presse | 2005.06.14
The embryonic origin of muscle stem cells
Researchers from the CNRS and the Institut Pasteur, members of the European Network of Excellence MYORES report on the embryonic origins of muscle stem cells. These results, published in two Nature papers on June 16th, 2005, lead to a better understanding of the muscle development. Press release Paris, june 15, 2005 Muscle stem cells exist in the embryo and in the...
-
Document de presse | 2005.04.13
The art of camouflaging the parasite responsible for malaria
Researchers from the Institut Pasteur and the CNRS have brought to light the unique mechanisms that allow the parasite responsible for malaria to fool the immune system of those it infects. In collaboration with researchers from the Walter and Eliza Hall Institute of Medical Research of Melbourne, they showed in two articles published in Cell that the parasite is capable of changing the...
-
Document de presse | 2005.01.16
Cervical cancer : developing a therapeutic vaccine
A candidate vaccine for treating cervical cancers has just been proven effective in animals by researchers at the Institut Pasteur in cooperation with the French National Health and Medical Research Institute (Inserm) and the French National Center for Scientific Research (CNRS), and by the company BT PHARMA*, an Institut Pasteur start-up company. This therapeutic vaccine is directed against a...
-
Document de presse | 2004.10.03
Legionnaire's disease : genomes of the Paris and Lens strains sequenced
Legionellosis or Legionnaire's disease affected more than 1,000 people in France in 2003 and caused nearly 130 deaths. This emerging disease is caused by Legionella pneumophila, an environmental bacterium that can grow in hot water systems. A team at the Institut Pasteur associated with the CNRS [French National Center for Scientific Research] and in collaboration with the National Reference...